71 centers in 10 countries & Canadian provinces are now recruiting female subjects with knee osteoarthritis, also known as ‘degenerative joint disease,’ for a 2-year Phase II study.
Target enrollment is 1,400. (An estimated 80% of the population has evidence of OA by age 65. It accounts for 25% of all primary care physician visits and half of all non-steroidal anti-inflammatory drug prescriptions in the U.S.)
This placebo-controlled study (ClinicalTrials.gov # NCT00565812) is sponsored by Pfizer. It will involve the drug code named SD-6010 – designed to inhibit the activity of inducible nitric oxide synthase (iNOS), a ‘signal’ enzyme in the body involved in local immune reaction/inflammation and tissue destruction in joints.
For more information about the trial, the outcome measures and inclusion requirements, and to contact a study center near you for further questions, see the trial listing at ClinicalTrials.gov.